|
|
|
| Preparation and Immunogenicity Studies on mRNA Vaccine Based on VP1 Gene of Porcine foot-and-mouth disease type O virus |
| DONG Jin-Jie1,2,3,4, WANG Hui-Bao2, WANG Fan2, DENG Rui-Xue2, LIU Ping2, CHEN Miao-Miao2, LI Yang-Fan2, ZHANG Yong1,4,* |
1 College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China;
2 China Agricultural Vet. Bio. Science and Technology Co., Ltd., Lanzhou 730046, China;
3 Lanzhou Veterinary Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China;
4 Gansu Key Laboratory of Animal Generational Physiology and Reproductive Regulation |
|
|
|
|
Abstract Foot-and-mouth disease (FMD) is one of the most important infectious diseases causing significant economic losses to the swine (Sus scrofa domesticus) industry. Vaccine immunization is still the one of main ways to prevent and control foot-and-mouth disease. Because Foot-and-mouth disease virus is easy to mutate, the antigen mismatch between candidate vaccine strains and epidemic strains will affect the immune efficacy of vaccine and the effect of disease control. According to the molecular and functional characteristics of structural protein VP1 (viral structural protein) gene, using the inactivated Porcine foot-and-mouth disease virus type O strain (O /MYA98/BY/2010) as the template, the structural protein VP1 gene was amplified and ligated into pSFV1 vector to construct the recombinant plasmid pSFV1-VP1. To obtain mRNA, the recombinant plasmid was treated by linearization and in vitro transcription, then the mRNA was transfected into baby hamster syrian kidney-21 (BHK-21) cells and verified its expression properly. After that, it was mixed with the liposome nanoparticles to immunize guinea pigs (Cavia porcellus), and the immune response and efficacy were detected. The results showed that the mRNA was expressed in BHK-21 cells after 24 h post-transfection evaluated by immunofluorescence assay (IFA) and Western blot; In guinea pigs immunized with the mRNA vaccine, specific antibody, neutralizing antibody, interleukin 4 (IL-4) and γ interferon (IFN-γ) in serum were significantly higher than those of guinea pigs. The mRNA vaccine could provide 4/4 protection against 50 times GPID50 (50% Guinea pig infectious dose) virus challenge in vaccinated guinea pigs, implying humoral and cellular immune response elicited by the developed mRNA vaccine with sound immunogenicity, which provides a new route for the development of foot-and-mouth disease emergency vaccine.
|
|
Received: 16 November 2021
|
|
|
|
Corresponding Authors:
* zhychy@163.com
|
|
|
|
[1] Alberer M, Gnad-Vogt U, Hong H S, et al.2017. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial[J]. The Lancet, 390(10101): 1511-1520.
[2] Brown F.2003. The history of research in foot-and-mouth disease[J]. Virus Research, 91(1): 3-7.
[3] Buschmann M D, Carrasco M J, Alishetty S, et al.2021. Nanomaterial delivery systems for mRNA vaccines[J]. Vaccines (Basel), 9(1): 65.
[4] Chahal J S, Khan O F, Cooper C L, et al.2016. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose[J]. Proceedings of the National Academy of Sciences of the USA, 113(29): E4133-E4142.
[5] Geall A J, Verma A, Otten G R, et al.2012. Nonviral delivery of self-amplifying RNA vaccines[J]. Proceedings of the National Academy of Sciences of the USA, 109(36): 14604-14609.
[6] Grubman M J, Baxt B.2004. Foot-and-mouth disease[J]. Clinical Microbiology Reviews, 17(2): 465-493.
[7] Kalinski P, Wieckowski E, Muthuswamy R, et al.2010. Generation of stable Th1/CTL-, Th2-, and Th17-inducing human dendritic cells[J]. Methods in Molecular Biology, 595: 117-133.
[8] Kowalczyk A, Doener F, ZanzingerK, et al.2016. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity[J]. Vaccine, 34(33): 3882-3893.
[9] Kramps T, Probst J.2013. Messenger RNA-based vaccines: Progress, challenges, applications[J]. Wiley Interdisciplinary Reviews RNA, 4(6): 737-749.
[10] Kranz L M, Diken M, Haas H, et al.2016. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy[J]. Nature, 534(7607): 396-401.
[11] Li K L, Wang C, Yang, F, et al.2021. Virus-host interactions in Foot-and-mouth disease virus infection[J]. Frontiers in Immunology, 12: 571509.
[12] Lundstrom K.2016. Self-replicating RNA viral vectors in vaccine development and gene therapy[J]. Future Virology, 11(5): 345-356.
[13] Lutz J, Lazzaro S, Habbeddine M, et al.2017. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines[J]. NPJ Vaccines, 2: 29.
[14] Mahapatra M, Parida S.2018. Foot and mouth disease vaccine strain selection: Current approaches and future perspectives[J]. Expert Review of Vaccines, 17(7): 577-591.
[15] Maruggi G, Chiarot E, Giovani C, et al.2017. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens[J]. Vaccine, 35(2): 361-368.
[16] Mateu M G.1995. Antibody recognition of picornaviruses and escape from neutralization: A structural view[J]. Virus Research, 38(1): 1-24.
[17] McCullough K C, De Simone F, Brocchi E, et al.1992. Protective immune response against foot-and-mouth disease[J]. Journal of Virology, 66(4): 1835-1840.
[18] Midoux P, Pichon C.2015. Lipid-based mRNA vaccine delivery systems[J]. Expert Review of Vaccines, 14(2): 221-234.
[19] Moschovakis G L, Bubke A, Dittrich-Breiholz O, et al.2012. Deficient CCR7 signaling promotes TH2 polarization and B-cell activation in vivo[J]. European Journal of Immunology, 42(1): 48-57.
[20] Orton R J, Wright C F, King D P, et al.2020. Estimating viral bottleneck sizes for FMDV transmission within and between hosts and implications for the rate of viral evolution[J]. Interface Focus, 10(1): 1-10.
[21] Pardi N, Hogan M J, Pelc R S, et al.2017. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination[J]. Nature, 543(7644): 248-251.
[22] Pardi N, Hogan M J, Porter F W, et al.2018. mRNA vaccines - a new era in vaccinology[J]. Nature Reviews Drug Discovery, 17(4): 261-279.
[23] Pepini T, Pulichino A M, Carsillo T, et al.2017. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design[J]. Journal of Immunology, 198(10): 4012-4024.
[24] Petsch B, Schnee M, Vogel A B, et al.2012. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection[J]. Nature Biotechnology, 30(12): 1210-1216.
[25] Richner J M, Himansu S, Dowd K A, et al.2017. Modified mRNA vaccines protect against Zika virus infection[J]. Cell, 168(6): 1114-1125.
[26] Schlake T, Thess A, Fotin-Mleczek M, et al.2012. Developing mRNA-vaccine technologies[J]. RNA Biology, 9(11): 1319-1330.
[27] Van Blargan L A, Himansu S, Foreman B M, et al.2018. An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections[J]. Cell Reports, 25(12): 3382-3392.
[28] Wang G, Pan L, Zhang Y, et al.2011. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge[J]. PLOS ONE, 6(11): e27605.
[29] Willems T, De Vleeschauwer A, Perez-Filgueira M, et al.2020. FMD vaccine matching: Inter laboratory study for improved understanding of r1 values[J]. Journal of Virological Methods, 276: 113786. |
|
|
|
